Jinyu Testing Medicine is a high-tech service enterprise, focusing on third-party medical testing and pathological diagnosis business. As one of the leading ICL (Medical Laboratory and Pathological Diagnosis Outsourcing) companies in China, Jinyu Medical is in a leading position in the industry in terms of business scale, market network coverage, testing items and technology platform.
The main business of Jinyu Medical is to provide a wide range of laboratory technology and scientific research technical services for more than 23,000 medical institutions nationwide. It covers six categories and 82 types of testing technologies, including physicochemical mass spectrometry, genomic testing, pathological diagnosis, biochemiluminescence testing, immunological testing and other comprehensive testing. Jinyu Medical provides outsourcing services for nearly 3,900 testing items, which can process more than 1500 million test specimens. In addition, based on the large sample and large database of oriental ethnicity, Jinyu Medical promotes the original innovation of the in vitro diagnostic industry and artificial intelligence diagnosis.
Jinyu Medical has established 49 central laboratories and more than 750 cooperative laboratories across the country. Its service network covers more than 90% of the country's population, and it has become a leading enterprise in the domestic third-party medical testing industry.
According to the latest disclosed report, Jinyu Medical has achieved remarkable performance results. Its revenue reached 63100 million yuan, and the net profit attributable to the parent reached 57.6 billion yuan. In particular, it is worth mentioning that the revenue from routine medical testing services reached 589.1 billion yuan, an increase of 1665%。Jinyu Medical's performance in the field of medical diagnostics remains strong.
Jinyu Medical has achieved significant growth in the fields of solid tumors, neurological and psychiatric diseases, infectious diseases, blood diseases, cardiovascular and endocrine diseases, with growth rates respectively. 24%, fully demonstrating its development strength.
At present, the reform of DRGS (diagnosis-related grouping) in China has been continuously promoted, the power of hospital terminal control fee has been enhanced, and the status and role of laboratory departments have undergone major changes. For hospitals, the laboratory department will change from a profit center to a cost center, and the proportion of specimen delivery will continue to increase. In addition, the laboratory self-built method (LDT) policy has begun to be piloted, which is expected to accelerate the growth of Jinyu Medical's special inspection business.
Jinyu Medical will continue to be committed to providing high-quality medical testing and pathological diagnosis services for medical institutions. Through continuous innovation and expansion of business scope, Jinyu Medical will meet the needs of hospitals and adapt to changes in the industry. At the same time, Jinyu Medical will also actively respond to the national medical reform policy, promote technological innovation and development in the field of medical testing, and make positive contributions to improving medical quality, promoting individualization and promoting the development of the health industry.